市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Replimune Group, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
-1.7
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | -1.67 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.51% |
| 机构持股比例 | 107.50% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Ridgeback Capital Investments L.P. | 30 Jun 2026 | 7,310,656 |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 25 Aug 2026 | CNBC | HHS plans new FDA deputy commissioner roles for technology and drugs, sources say |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合